Related references
Note: Only part of the references are listed.Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease
Marc S. Sabatine et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients
Matthew A. Allison et al.
JOURNAL OF VASCULAR SURGERY (2007)
Molecular basis for susceptibility of plasma platelet-activating factor acetylhydrolase to oxidative inactivation
Amy N. MacRitchie et al.
FASEB JOURNAL (2007)
Ratio of LDL- to HDL-associated platelet-activating factor acetylhydrolase may be a marker of inflammation in patients with paroxysmal atrial fibrillation
Keisuke Okamura et al.
CIRCULATION JOURNAL (2007)
Phospholipase action of platelet-activating factor acetylhydrolase, but not paraoxonase-1, on long fatty acyl chain phospholipid hydroperoxides
Tamas Kriska et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Predicting the risk of cardiovascular disease - Where does lipoprotein-associated phospholipase A(2) fit in?
Natalie Khuseyinova et al.
MOLECULAR DIAGNOSIS & THERAPY (2007)
Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis
Frank D. Kolodgie et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Clinical aspects of plasma platelet-activating factor-acetylhydrolase
Ken Karasawa
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2006)
The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men
Yangsoo Jang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Novel candidate genes in unstable areas of human atherosclerotic plaques
Marianna Papaspyridonos et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients
JP Corsetti et al.
CLINICAL CHEMISTRY (2006)
PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin
EC Papavasiliou et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target
CH Macphee et al.
CURRENT OPINION IN PHARMACOLOGY (2006)
Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis - The Rotterdam study
I Kardys et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases
DM Stafforini et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Lp-PLA(2): A new kid on the block
Andrew Zalewski et al.
CLINICAL CHEMISTRY (2006)
Altered lipoprotein subclass distribution and PAF-AH activity in subjects with generalized aggressive periodontitis
ML Rufail et al.
JOURNAL OF LIPID RESEARCH (2005)
Lipoprotein associated phospholipase A2 as a target of therapy
CH Macphee et al.
CURRENT OPINION IN LIPIDOLOGY (2005)
Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect
HJ Milionis et al.
THYROID (2005)
Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome
E Rizos et al.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2005)
Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke - The Rotterdam Study
HHS Oei et al.
CIRCULATION (2005)
Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up
ES Brilakis et al.
EUROPEAN HEART JOURNAL (2005)
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study
CM Ballantyne et al.
CIRCULATION (2004)
Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity
AP Tambaki et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2004)
Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population -: Results from the 14-year follow-up of a large cohort from southern Germany
W Koenig et al.
CIRCULATION (2004)
Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase - Implication for atherosclerosis
M Eisaf et al.
BIOCHEMICAL PHARMACOLOGY (2003)
Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus
T Kujiraoka et al.
JOURNAL OF LIPID RESEARCH (2003)
Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins
V Tsimihodimos et al.
JOURNAL OF LIPID RESEARCH (2003)
Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress
H Noto et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
The discoverv of SB-435495:: A potent, orally active inhibitor of lipoprotein-associated phospholipase A2 for evaluation in man
JA Blackie et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2002)
A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women
GJ Blake et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2001)
Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages
KLH Carpenter et al.
FEBS LETTERS (2001)
PAF acetylhydrolase gene polymorphisms and asthma severity
DM Stafforini
PHARMACOGENOMICS (2001)
Platelet-activating factor acetylhydrolases: Broad substrate specificity and lipoprotein binding does not modulate the catalytic properties of the plasma enzyme
JH Min et al.
BIOCHEMISTRY (2001)
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease.
CJ Packard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice
G Theilmeier et al.
FASEB JOURNAL (2000)
Share Paper
